Pfizer's Lyrica fails to show post-traumatic nerve pain benefit; FDA approves Lilly lung cancer med Portrazza;

> Pfizer's ($PFE) Lyrica has failed to show benefit in patients suffering from a type of post-traumatic nerve pain in a late-stage study. Report

> The FDA has approved Eli Lilly's ($LLY) Portrazza to treat advanced squamous non-small cell lung cancer. Release

> Mylan has launched Clozapine orally disintegrating tablets--a generic of Jazz Pharmaceutical's ($JAZZ) FazaClo--in the U.S. Release

> The U.K.'s cost effectiveness gatekeepers have recommended two treatments for treating recurrent ovarian cancer, but they've rejected a further three. Report

And Finally... The Gaucher disease treatment market may reach $1.16 billion by 2024, GlobalData predicts. More

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.